References
Stahlmann R, et al. Drug Saf 9: 397–403, 1993
Schaad UB. Drugs 35 (Suppl. 3): 37–41, 1993
Stahlmann R, et al. Arch Toxicol 64: 193–204, 1990
Schaad UB. Pediatr Infect Dis J 11: 1043–1046, 1992
Machida M, et al. Toxicol App Pharmacol 105: 413–412, 1990
Adam D. Rev Infect Dis 11 (Suppl. 5): 1113–1116, 1989
Schaad UB, Wedgwood-Krucko J. Infection 15: 165–168, 1987
Samuelson WM, et al. Ann Pharmacother 27: 302–303, 1993
Chysk V, et al. Infection 19: 289–296, 1991
Orenstein DM, et al. Clin Pediatr 32: 504–506, 1993
Pertuiset E, et al. Rev Rheum Mal Osteo-Articul 56: 735–740, 1989
Danisoviovà A, et al. Chemotherapy 40: 209–214, 1994
Schaad UB, Wedgwood J. J Antimicrob Chemother 30: 414–416, 1992
Schaad UB, et al. Pediatr Infect Dis J 11: 1047–1049, 1992
Norrby SR, Lietman PS. Drugs 45 (Suppl.): 59–64, 1993
Rights and permissions
About this article
Cite this article
Fluoroquinolones probably justified for serious paediatric infections despite arthropathy risk. Drugs Ther. Perspect 3, 10–12 (1994). https://doi.org/10.2165/00042310-199403100-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199403100-00005